ALL POINTS TO CONTINUED DEVELOPMENT AND GROWTH THROUGH EXPANSION ****INVEST WISELY****
WITH EXTREMELY LOW SHARE STRUCTURE 500 MILLION AUTHORIZED 426 MILLION OUTSTANDING
HERES SOME JUICY 2018 NUMBERS - W/O NEW LOCATION ACQUIRED 3/30/18, these revenues will start to be recognized June 30, 2018 Scripts: 109,600 a 24% increase compared to May 31, 2017 Net Revenue: $8.53 million, a $280,000+ increase compared to May 31, 2017 340B Sales: $2.35 million, a $1.49 million+ increase compared to May 31, 2017 Annualized, 2018 340B Sales are estimated at $6.2 Million, that's nearly a 125% increase of 2017's $2.75 Million. PharmCoRX is obviously increasing the number of customers.
KEY PHARMACIST COMPENSATION SAVINGS: $473,000 estimated for 2018 Management restructured Key Pharmacist agreement October 1, 2017 to reduce costs, which resulted in a savings of $173,000 compared to last year as recognized in 1st Quarter Results with this F/S Note: During the three months ended March 31, 2018 and 2017, payments to the pharmacist were approximately $87,000 and $260,000, respectively. $87K x 4 = $348 compared to FY 2017 of $821K. This puts us on pace for savings of over $473,000 for 2018
Let’s Take a Very Close Look with the Eyeball on 1st Quarter Results So we reported $(642,000) Loss. What really makes up that Loss and Is True Profitability Reflected. Let’s start from the Net Loss and then dive into the expenses and see what’s really related to Operations. This completely agrees with F/S information below, which doesn’t take it as far to perform the addbacks to assess RXMD’s true profitability.
Then let’s observe increase in revenue last year. JUST KEEPS INCREASING YOY Then check out increase in revenue from the last 2 years. Overall G - FY 2013 = $9.3 million R - FY 2014 = $11.3 million O - FY 2015 = $13.7 million W - FY 2016 = $18.3 million (AUDITED) T - FY 2017 = $20.1 million (AUDITED) H - FY 2018 = $8.53 million (5 months) does not include 340B revenues
LET'S TALK ABOUT INCOME FROM PREVIOUS YEARS Shall We . . . FY 2017 = $49,251 AUDITED Net Income, and w/o Discontinued Operations Net Income is $139,251 FY 2016 = $209,319 AUDITED Net Income, and w/o Discontinued Operations Net Income is $259,319 Yes it did go down by $150,000, but quite explainable with $90,000 from discontinued operations and the information detailed below and still extraordinary when you consider the improvement from 2015 and 2014, FY 2015 = $(1,219,000) Net Loss FY 2014 = $(1,009,000) Net Loss
Now let’s analyze where some of expenses effecting additional net income has been applied to development, growth, and expansion initiatives. Growing, Growing, Growing. Everything says they are using money to GROW.
Available Cash Is Building Up !!! End Of 2017 = $419,000 1st Qtr 2018 = $1,261,000 Million FY 2017 A/R = $1,270,114 1st Qtr 2018 = $1,128,000 Cash and A/R Combined Cash Assets December 31, 2017 = $1,689,000 March 31, 2018 = $2,389,000 In awesome position, although a portion will go to acquisition. An increase of over $700K in cash assets and $1.2 million overall in cash assets.
EVERYTHING IS MOVING FORWARDS AND LOOKING GREAT !!! Another Acquisition Scheduled for 2018 Another Acquisition, SEC Reporting Compliance, and NASDAQ Uplifting for early 2019